BV-ARA-U VS ACYCLOVIR IN LOCALIZED HERPES ZOSTER IN IMMUNOCOMPROMISED PTS

BV-ARA-U 与阿昔洛韦在免疫功能低下患者局部带状疱疹中的比较

• 批准号: 3738910
• 负责人: RICHARD J WHITELY
• 金额: --
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3738910
• 关键词: AIDS; AIDS therapy; acute disease /disorder; acyclovir; antiviral agents; clinical trials; drug screening /evaluation; human subject; human therapy evaluation; microorganism disease chemotherapy; shingles; uracil analog

This is a randomized, double-blind, controlled trial to compare the efficacy of BV-ara-U (40mg/d) versus acyclovir (800 mg five times daily) in the treatment of acute, localized, non-trigeminal zoster in immunocompromised patients.

这是一项随机、双盲、对照试验， BV-ara-U（40 mg/d）与阿昔洛韦（800 mg，每日5次）的疗效 治疗急性、局部、非三叉神经带状疱疹， 免疫功能低下的患者。